Lipoprotein (a) levels in those with high molecular weight apo (a) isoforms may remain low in a significant proportion of patients with end-stage renal disease

Nephrology Dialysis Transplantation

Volumn 18, Issue 9, 2003, Pages 1848-1853

  Parsons, Darren S ^a   Reaveley, David A ^a   Pavitt, Darrell V ^a   Misra, Madhukar ^a   Brown, Edwina A ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Lipoprotein (a); Renal failure

Indexed keywords

APOLIPOPROTEIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROTEIN; LIPOPROTEIN A; THALLIUM;

ADULT; AMPUTATION; ANAMNESIS; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ANGIOPLASTY; ARTICLE; BLOOD SAMPLING; BRAIN ATHEROSCLEROSIS; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; HEART INFARCTION; HEART SCINTISCANNING; HUMAN; INTERMITTENT CLAUDICATION; KIDNEY FAILURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MOLECULAR WEIGHT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; VASCULAR DISEASE;

AGED; APOLIPOPROTEINS A; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEIN(A); MALE; MIDDLE AGED; PROTEIN ISOFORMS; VASCULAR DISEASES;

EID: 0041883627     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg276     Document Type: Article

References (23)

1. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994; 9: 1136-1142
2. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp (a) glycoprotein phenotypes: inheritance and relation to Lp (a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80: 458-465
3. Milionis HJ, Elisaf MS, Tselepis A, Bairaktari E, Karabina SA, Siamopoulos KC. Apolipoprotein (a) phenotypes and lipoprotein (a) concentrations in patients with renal failure. Am J Kidney Dis 1999; 33: 1100-1106
4. Stenvinkel P, Heimburger O, Tuck CH, Berglund L. Apo (a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 1998; 53: 1336-1342
5. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8: 609-613
6. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. High serum lipoprotein (a) concentrations in uraemic patients treated with continuous ambulatory peritoneal dialysis patients. Clin Nephrol 1992; 38: 271-276
7. Kronenberg F, Konig P, Neyer U et al. Multi-centre study of lipoprotein (a) and apolipoprotein (a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110-120
8. Dieplinger H, Lackner C, Kronenberg F et al. Elevated plasma concentrations of lipoprotein (a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein (a). J Clin Invest 1993; 91: 397-401
9. Cressman MD, Heyka RJ, Paganini EP, O'Neil S, Skibinski CI, Hoff HF: Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475-482
10. Gazzaruso C, Bonetti G, Garzaniti A et al. Increased plasma concentrations of lipoprotein (a) for every phenotype of apolipoprotein (a) in patients with chronic renal failure treated by haemodialysis. Nutr Metab Cardiovasc Dis 1996; 6: 203-210
11. Kronenberg F, Kuen E, Ritz E et al. Lipoprotein (a) serum concentrations and apolipoprotein (a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11: 105-115
12. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Lipids and lipoprotein (a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 1995; 10: 354-357
13. Kronenberg F, Kathrein H, Konig P et al. Apolipoprotein (a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 1994; 14: 1405-1411
14. Koda Y, Nishi S, Suzuki M, Hirasawa Y. Lipoprotein (a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int 1999; 56 [Suppl 71]: S251-S253
15. Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997; 12: 2603-2611
16. Koch M, Kutkuhn B, Trenkwalder E et al. Apolipoprotein B, fibrinogen, HDL cholesterol and apolipoprotein (a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997; 8: 1889-1898
17. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull Wld Hlth Org 1962; 27: 645-58
18. Faucher C, Doucet C, Baumelou A, Chapman J, Jacobs C, Thillet J. Elevated Lp (a) levels in primary nephrotic syndrome. Am J Kidney Dis 1993; 22: 808-813
19. Perombelon YF, Soutar AK, Knight BL. Variation in lipoprotein (a) concentration associated with different apolipoprotein (a) alleles. J Clin Invest 1994; 93: 1481-1492
20. Wanner C, Rader D, Bartens W et al. Elevated plasma lipoprotein (a) in nephrotic syndrome. Ann Intern Med 1993; 119: 263-269
21. Kronenberg F, Trenkwalder E, Lingenhel A et al. Renovascular arteriovenous differences in Lp (a) plasma concentrations suggest removal of Lp (a) from the renal circulation. J Lipid Res 1997; 38: 1755-1763
22. Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina S, Hobbs HH. Apolipoprotein (a) kringle 4-containing fragments in urine: relationship to plasma levels of lipoprotein (a). J Clin Invest 1996; 97: 858-864
23. Kostner KM, Oberbauer R, Hoffmann U, Stefenelli T, Maurer G, Watschinger B. Urinary excretion of apo (a) in patients after kidney transplantation. Nephrol Dial Transplant 1997; 12: 2673-2678